Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals (Nasdaq: KALV) appointed Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. Both executives bring 25+ years of industry experience to support the global launch of EKTERLY. Mr. Arif’s background spans technical operations, manufacturing, and global launches; Ms. Aspesi’s background spans HR leadership across biopharma and healthcare.

Each new hire will receive an inducement option to purchase 100,000 shares (grant date October 8, 2025), exercise price equal to the Nasdaq closing price on the grant date, vesting over four years (25% at one year, then monthly), and a 10-year term.

KalVista Pharmaceuticals (Nasdaq: KALV) announced on October 3, 2025 that its compensation committee granted inducement stock options to two newly hired employees totaling 30,000 shares on October 1, 2025.

The options’ exercise price equals the closing price on the first trading day with a reported close following the grant date. Vesting: 25% at one year, then monthly vesting over the next three years, subject to continued service. Each option carries a 10-year term and is governed by KalVista’s Inducement Equity Incentive Plan and stock option agreements. Grants comply with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Bethany L. Sensenig to its Board of Directors and Audit Committee, effective October 1, 2025. Ms. Sensenig brings over 20 years of leadership experience in finance, corporate strategy, and commercial operations to KalVista.

Currently serving as CFO and Head of Operations at Radius Health, Sensenig's extensive experience includes roles as CFO and Interim CEO at 9 Meters Biopharma, and a 13-year tenure at Biogen where she managed revenue exceeding $1B across 30 countries. The appointment comes as KalVista continues the global commercialization of EKTERLY, their first-in-class oral on-demand therapy for hereditary angioedema (HAE).

KalVista Pharmaceuticals (NASDAQ:KALV) announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress in Düsseldorf, Germany, scheduled for October 2-4, 2025.

The presentations will focus on various aspects of EKTERLY® (sebetralstat) in treating Hereditary Angioedema (HAE) attacks. Key topics include time to end of HAE attack progression, effectiveness in European participants, treatment of mucosal attacks, impact on patient anxiety, treatment efficacy in combination with berotralstat, and barriers to timely treatment in German patients.

KalVista Pharmaceuticals (NASDAQ: KALV) has priced an upsized offering of $125.0 million in 3.250% Convertible Senior Notes due 2031, increased from the previously announced $110.0 million. The notes will mature on October 1, 2031, with initial purchasers having an option to buy an additional $18.75 million in notes.

The notes will be convertible at an initial rate of 59.4919 shares per $1,000 principal amount, equivalent to approximately $16.81 per share, representing a 30% premium over the current stock price of $12.93. KalVista expects net proceeds of approximately $120.8 million, which will be used for working capital, general corporate purposes, and the commercialization of EKTERLY.

KalVista Pharmaceuticals (NASDAQ: KALV) has announced plans to offer $110.0 million in Convertible Senior Notes due 2031 through a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $15.0 million in notes. The notes will be senior, unsecured obligations with semi-annual interest payments.

The notes will mature on October 1, 2031, with conversion options available under specific conditions. KalVista can settle conversions in common stock, cash, or a combination thereof. The company plans to use the proceeds for working capital, general corporate purposes, and the commercialization of EKTERLY, with potential allocation for future investments and acquisitions.

KalVista Pharmaceuticals (NASDAQ:KALV) has received approval from both the European Commission and Swissmedic for EKTERLY® (sebetralstat), marking a significant milestone as the first and only oral on-demand treatment for hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.

The approval is based on the phase 3 KONFIDENT trial, the largest HAE clinical study to date, which demonstrated EKTERLY's superior efficacy over placebo in providing faster symptom relief and attack resolution. The trial involved 136 HAE patients across 66 clinical sites in 20 countries.

KalVista plans to launch EKTERLY first in Germany in Q4 2025, followed by Switzerland in H2 2026. The EC approval covers all 27 EU member states plus Iceland, Liechtenstein, and Norway, with 10 years of market exclusivity granted through orphan designation.

KalVista Pharmaceuticals (NASDAQ:KALV) reported significant progress in Q1 fiscal 2025, highlighted by the FDA approval and launch of EKTERLY®, the first oral on-demand treatment for hereditary angioedema (HAE). The company received 460 patient start forms in just eight weeks post-launch, representing nearly 5% of the US HAE patient population.

The company achieved $1.4 million in net product revenue following EKTERLY's mid-July launch. KalVista secured UK approval and received a positive CHMP opinion recommending EU approval, with a final decision expected in October 2025. The company maintains a strong financial position with $191.5 million in cash, providing runway into 2027.

KalVista Pharmaceuticals (NASDAQ:KALV) has scheduled a live webcast for September 11, 2025, at 8:30 a.m. ET to provide an operational update and release its financial results for the fiscal quarter ended July 31, 2025. Investors can access the webcast through the Investors section of KalVista.com. A replay of the presentation will remain available for at least 30 days after the event.